An MR contrast agent for blood pool imaging once known as Vasovist reappeared at RSNA 2009 under the new moniker Ablavar.
An MR contrast agent for blood pool imaging once known as Vasovist reappeared at RSNA 2009 under the new moniker Ablavar. Marketing rights to the agent, which the FDA approved a year ago, were sold by Epix Pharmaceuticals for the U.S., Canadian, and Australian markets to Lantheus Medical in April 2009. Lantheus is now working out with the FDA the final labeling details regarding the agent.
The company is aiming for a hard launch of the blood pool agent early next year, pending final labeling from the FDA. The coming U.S. marketing campaign will promote MR procedures enhanced with the newly branded Ablavar as a less invasive option than x-ray angiography for imaging patients with known or suspected peripheral vascular disease, the specific application approved by the FDA for marketing. Lantheus will leverage sales channels used for its other products, including the technetium-based radiotracer Cardiolite and ultrasound contrast agent Definity.
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
New Literature Review Assesses Merits of Cardiac MRI After Survival of Sudden Cardiac Arrest
April 19th 2024While noting inconsistencies with the diagnostic yield of cardiac MRI in patients who survived sudden cardiac arrest, researchers cited unique advantages in characterizing ischemic cardiomyopathy (ICM) and facilitating alternate diagnoses.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.